Idiopathic Parkinson’s disease and Schizophrenia: Dilemma in diagnosis and treatment

  • Sneha Sharma Lady Hardinge Medical College, New Delhi, India.
  • Nitin Aggarwal Lady Hardinge Medical College, New Delhi, India.
Keywords: schizophrenia, Parkinson’s disease

Abstract

The relationship between schizophrenia and idiopathic Parkinson’s disease is still not clear and rare when they coexist. Diagnosing coexisting schizophrenia and idiopathic Parkinson’s disease is a chal-lenge, especially in developing countries due to lack of experts and advance imaging facilities. Treatment options are also limited. A 58- year- old male was admitted due to relapse of psychotic symptoms following non-compliance to antipsychotic medications. The patient was previously diag-nosed with schizophrenia and later developed Parkinson’s disease while non-compliant to antipsy-chotic medications. While the patient was at our center, his detailed history was taken and general physical examination was done to distinguish Parkinson’s disease from anti-psychotic induced ex-trapyramidal symptoms. All the routine investigations were within normal limits. This case report highlights the clinical factors that help make a distinction and help use appropriate drugs to manage schizophrenia with comorbid Parkinson’s disease in developing countries, where lack of precise di-agnostic imaging modalities interferes in making a conclusive diagnosis.

Author Biographies

Sneha Sharma, Lady Hardinge Medical College, New Delhi, India.
Senior resident, Department of Psychiatry
Nitin Aggarwal, Lady Hardinge Medical College, New Delhi, India.
Senior resident, Department of Psychiatry

References

Carlsson A, Carlsson ML. A dopaminergic deficit hypothesis of schizophrenia: The path to discovery. Dialogues Clin Neurosci. 2006;8(1):137–42.

Dauer W, Przedborski S. Parkinson’s disease: Mechanisms and models. Vol. 39, Neuron. 2003. p. 889–909.

Grover S, Sahoo S, Goyal M. Schizophrenia with comorbid idiopathic parkinson’s disease: A difficult clinical management scenario. Indian J Psychol Med. 2017;39(6).

de Jong MH, Zemel D, Van Gool AR. Clinical aspects of comorbid schizophrenia and idio-pathic Parkinson’s disease. Clin Schizophr Relat Psychoses [Internet]. 2014;8(1):36–40. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23428786

Winter C, Juckel G, Plotkin M, Niehaus L, Kupsch A. Paranoid schizophrenia and idiopathic Parkinson’s disease do coexist: A challenge for clinicians [1]. Vol. 60, Psychiatry and Clinical Neurosciences. 2006. p. 639.

Gadit A. Schizophrenia and Parkinson’s disease: Challenges in management. BMJ Case Rep. 2011;

Lam RW. Chronic schizophrenia and idiopathic Parkinson’s disease. Can J Psychiatry. 1993;38(2):75–7.

Plotkin M, Amthauer H, Klaffke S, Kühn A, Lüdemann L, Arnold G, et al. Combined 123I-FP-CIT and 123I-IBZM SPECT for the diagnosis of parkinsonian syndromes: Study on 72 patients *. J Neural Transm. 2005;112(5):677–92.

Friedman JH. Managing idiopathic Parkinson’s disease in patients with schizophrenic disor-ders. Parkinsonism Relat Disord [Internet]. 2011;17(3):198–200. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1353802010002993

Lan CC, Su TP, Chen YS, Bai YM. Treatment dilemma in comorbidity of schizophrenia and idiopathic Parkinson’s disease. Gen Hosp Psychiatry. 2011;33(4).

Menza MMA, Palermo B, Mark M. Quetiapine as an alternative to clozapine in the treatment of dopamimetic psychosis in patients with Parkinson’s disease. Ann Clin Psychiatry. 1999;11(3):141–4.

Ruggieri S, De Pandis MF, Bonamartini A, Vacca L, Stocchi F. Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson’s disease. Clin Neuropharmacol [Internet]. 1997;20(3):204–9. Available from: http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=psyc3&NEWS=N&AN=1997-04724-001%5Cnhttp://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=med4&NEWS=N&AN=9197942

Fernández-Corcuera P, Aguilar S, Viçens V, Mora J, Benitez A, García-Burillo A, et al. ECT in a patient with Parkinson’s disease and schizophrenia, with dopamine transporter visualisation using 123I-Ioflupane SPET. J Neural Transm. 2011;118(4):647–50.

Meltzer HY, Mills R, Revell S, Williams H, Johnson A, Bahr D, et al. Pimavanserin, a seroto-nin(2A) receptor inverse agonist, for the treatment of parkinson’s disease psychosis. Neuro-psychopharmacology [Internet]. 2010;35(4):881–92. Available from: http://www.nature.com/npp/journal/v35/n4/full/npp2009176a.html#References

Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, et al. Pimavanserin for patients with Parkinson’s disease psychosis: A randomised, placebo-controlled phase 3 trial. Lancet. 2014;383(9916):533–40.

Published
2019-05-08
How to Cite
1.
Sharma S, Aggarwal N. Idiopathic Parkinson’s disease and Schizophrenia: Dilemma in diagnosis and treatment. Iran J Psychiatry. 14(2):179-181.
Section
Case Report(s)